Back to search

Ritanserin, a Selective 5-HT2/1C Antagonist, and Negative Symptoms in Schizophrenia

Data up to Jan 2025

Published1993
Citations153
References22

Total Citations Per Year

Abstract

References (22)

The Brief Psychiatric Rating Scale

1962 • 10,683 citations

A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

1970 • 3,213 citations

Negative Symptoms in Schizophrenia

1982 • 2,228 citations

Molecular pathology of schizophrenia: more than one disease process?

1980 • 1,877 citations

Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons

1975 • 874 citations

Part III. Speculations on the Processes That Underlie Schizophrenic Symptoms and Signs

1974 • 572 citations

MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA

1978 • 464 citations

Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

1985 • 444 citations

The Distinction of Positive and Negative Symptoms

1991 • 404 citations

Differential effects of amphetamine and neuroleptics on negative Vs. positive symptoms in schizophrenia

1980 • 347 citations

The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors.

1990 • 280 citations

5-Hydroxytryptamine-2 antagonist increases human slow wave sleep

1986 • 231 citations

Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin‐S2 receptor blocker

1986 • 194 citations

Social Adjustment and Cognitive Performance of High-Risk Children

1985 • 178 citations

Dopamine receptors, neuroleptics, and schizophrenia

1981 • 171 citations

Behavioral and 5-HT antagonist effects of ritanserin: A pure and selective antagonist of LSD discrimination in rat

1985 • 143 citations

5-HT2 Antagonist Ritanserin in Neuroleptic-Induced Parkinsonism

1990 • 105 citations

5‐HT2 receptor antagonism in dysthymic disorder: a double‐blind placebo‐controlled study with ritanserin

1991 • 82 citations

Ritanserin, A 5-HT2 Receptor Blocker, as Add-on Treatment in Narcolepsy

1991 • 39 citations

Ritanserin in the treatment of generalized anxiety disorders: A placebo‐controlled trial

1988 • 33 citations

Ritanserin in schizophrenic patients.

1989 • 8 citations

Pharmacology, Function and Adaptive Regulation of 5HT-1c Receptors

1990 • 1 citations

Cited By (0)

Loading...
Ritanserin, a Selective 5-HT2/1C Antagonist, and Negative Symptoms in Schizophrenia (1993) – The British Journal of Psychiatry | Metascience Observatory Explorer